Biospecimen Applications
New applications for biospecimens are currently being accepted for the following project types.
Application periods close on the dates indicated at 11:59 PM EST.
- EPPT Biospecimens Nov 13
The Division of Cancer Prevention conducts systematic early clinical development of promising preventive agents through its Phase 0/I/II Cancer Prevention Clinical Trials Program, consisting of the Consortia for Early Phase Prevention Trials (2012-2024) and the Cancer Prevention Clinical Trials Network (CP-CTNet, 2019-current).
Cancer prevention drug discovery is identifying many new agents, including an increasing number of agents that intervene in specific molecular pathways thought to be critical to cancer development. Since cancer prevention studies focus on high-risk populations that do not necessarily harbor a detectable cancer, these studies require extensive biomarker analysis, investigation of the biologic effects of the cancer preventive agents on their intended molecular targets, and correlation with clinically relevant endpoints.
Learn About EPPT
Get a detailed description of the trial, explaining how and what data were collected. The main findings of the trial and counts of cancers are available as well.
Learn More about EPPT
Browse EPPT Studies
The data and biospecimens from several of these Early Phase Prevention Trials studies are available for request on CDAS.
Browse EPPT StudiesSubmit an EPPT Project Proposal
To gain access to available EPPT data and/or biospecimens, you must submit a project proposal. These are reviewed by NCI. If your project is approved, you will be required to complete a Data Transfer Agreement (and a Material Transfer Agreement, if applicable) before you will be granted access.
Available Project Proposals
There are two types of EPPT projects. Choose one to begin a new project proposal.
Early Phase Prevention Trials Goals
- To efficiently design and conduct early phase clinical trials necessary to assess the potential of cancer preventive agents of various classes, many of which are directed at molecular targets which have been shown to be expressed in intraepithelial neoplasia (IEN).
- To characterize the biological effects of new cancer preventive agents on their defined molecular targets as well as on multiple endpoints associated with carcinogenesis, such as proliferation, apoptosis, growth factor expression, oncogene expression, and others. Correlation of these effects with clinically relevant endpoints is required.
- To develop further scientific insights into the mechanisms of cancer prevention by the agents examined and to continue to develop novel potential markers as determinants of response.
Trial Data
The de-identified data collected in each trial is available for other research. For each trial the data is presented in two formats:
Biospecimens
A wide variety of biospecimens were collected from the various trials including: blood clots, buffy coat, cells, DNA, plasma, red blood cells, RNA, secretions, serum, stool, tissue, urine and whole blood cells. These biospecimens are stored at the PLCO Biorepository in Frederick, Maryland.
Biospecimen Applications
New applications for biospecimens are currently being accepted for the following project types.
Application periods close on the dates indicated at 11:59 PM EST.
- EPPT Biospecimens Nov 13
Approved Projects
View approved projects that used EPPT data. Project summaries, aims, collaborators and more are available.
Browse 1 ProjectsPublications
Browse the complete list of published articles on EPPT data, including authors, journal names, and more.
Search 24 Publications